MYCOF - Mydecine Provides Bl-Weekly Status Report
(TheNewswire)
Vancouver, British Columbia – TheNewswire - May 16, 2024—Mydecine Innovations Group Inc. (the “ Company ”) (CSE:MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) provides this update on the status of a management cease trade ordergranted on May 2, 2024 (the " MCTO ") by theBritish Columbia Securities Commission under National Policy 12-203– Management Cease Trade Order (" NP 12-203 ").
On May 3, 2024, the Company announced that, for reasonsdisclosed in the news release, there would be a delay in the filing ofits financial statements and accompanying management’s discussionand analysis for the fiscal year ended December 31, 2023 (the" AnnualFilings ") beyond the period prescribedunder applicable Canadian securities laws (the " Default Announcement ").
The Company reports that the audit is progressing andwill provide a further update on the timing of its Annual Filings onor about May 30, 2024.
During the MCTO, the general investing public willcontinue to be able to trade in the Company's listed common shares.However, the Company's Chief Executive Office and Chief FinancialOfficer will not be able to trade in the Company's commonshares.
Other than as disclosed in this news release, there areno material changes to the information contained in the DefaultAnnouncement. The Company confirms that it intends to satisfy theprovisions of NP 12- 203 and will continue to issue bi-weekly defaultstatus reports for so long as it remains in default of the AnnualFilings requirement.
The Directors of Mydecine take responsibility for thisannouncement.
This announcement contains inside information for thepurposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 asit forms part of UK domestic law by virtue of the European Union(Withdrawal) Act 2018 ("MAR"), and is disclosed inaccordance with the Company's obligations under Article 17 ofMAR.
On behalf of the Board of Directors,
MYDECINE INNOVATIONS GROUP INC.
Joshua Bartch
Chief Executive Officer
AQSE Corporate Advisor
Novum Securities Limited Tel:+44 (0)207 399 9400
David Coffman/ George Duxberry
About Mydecine Innovations Group Inc.
Mydecine Innovations Group™ is a biotechnologycompany developing the next generation of innovative medications andtherapies to address mental health disorders such as nicotineaddiction and posttraumatic stress disorder (PTSD). The core strategyblends advanced technology with an elaborate infrastructure for drugdiscovery and development. Mydecine's dedicated multinational teamconstantly develops new paths for breakthrough treatment solutions inareas with considerable unmet needs. By collaborating with some of theworld's leading specialists, the Company aspires to responsibly speedup the development of breakthrough medications to provide patientswith safer and more effective treatmentsolutions. At the same time, Mydecine's approach focuses on the nextgeneration of psychedelic medicine by creating innovative compoundswith unmatched therapeutic potential through its clinical trialefforts with worldclass scientific and regulatory expertise.
Learn more at: https://www.mydecine.com/ and follow thecompany on Twitter, LinkedIn, YouTube, and Instagram.
Forward-looking Information Statement
This news release may containcertain “forward-looking statements” and “forward-lookinginformation” within the meaning of applicable Canadian and UnitedStates securities laws. When used in this news release, the words“anticipate”, “believe”, “estimate”, “expect”,“target, “plan”, “forecast”, “may”, “schedule” andother similar words or expressions identify forward-looking statementsor information. These forward-looking statements or information mayrelate to the anticipated timing for the filing of the Annual Filings,and other factors or information. Such statements represent theCompany’s current views with respect to future events and arenecessarily based upon a number of assumptions and estimates that,while considered reasonable by the Company, are inherently subject tosignificant business, economic, competitive, political and socialrisks, contingencies and uncertainties. Many factors, both known andunknown, could cause results, performance or achievements to bematerially different from the results, performance or achievementsthat are or may be expressed or implied by such forward-lookingstatements. The Company does not intend, and does not assume anyobligation, to update these forward-looking statements or informationto reflect changes in assumptions or changes in circumstances or anyother events affections such statements and information other than asrequired by applicable laws, rules and regulations
NEITHER THE CSE NOR ITS REGULATIONS SERVICES PROVIDERHAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OFTHIS RELEASE.
Copyright (c) 2024 TheNewswire - All rights reserved.